Hearing Aids: Innovators Must Change the Channel
This article was originally published in Start Up
Ten percentage of the population in industrialized companies could benefit from hearing aids, and since the market remains 80% unpenetrated, new hearing aid companies and their financial backers see an enormous opportunity. But the hearing industry presents unique challenges compared to other medical device markets; the poor performance of past devices keeps people from buying hearing aids, as does the lack of reimbursement. Profitability is difficult for manufacturers to achieve, because manufacturing of the custom devices doesn't benefit from economies of scale. Finally, small companies have a tough time getting past the gatekeepers of the hearing industry--audiologists who have entrenched relationships with dominant manufacturers. New companies are entering the market with widely different approaches, some based on technology, some based on changing distribution channels. For some, the new approaches have clearly failed; others are embarking on new strategies that have yet to play out.
You may also be interested in...
Align Technology emerged from an unlikely source-two second-year Stanford business students with no previous start-up experience. These entrepreneurs were able to sign on major venture backers in a field which has never before attracted much interest from medical device investors: orthodontics. The founders' idea was that, by using advanced product design and manufacturing processes, the company could produce the Invisalign system of removable, clear plastic dental appliances that, for certain orthodontic patients, particularly adults-a large untapped market--could take the place of traditional metal braces. The challenge for the new company: to tap into a fragmented physician market not accustomed to new technology, moreover with a consumer-preferred device.
While many ideas for new devices originate with physicians, the true doctor/entrepreneur is rare. Rodney Perkins is one of the few who's actually been successful at it.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.